None
Quote | OSE Immunotherapeutics SA (OTCMKTS:ORPOF)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $4.00 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 02/12/2020 04:41:07 pm |
News | OSE Immunotherapeutics SA (OTCMKTS:ORPOF)
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 Ingelheim, Germany and Nantes, France, 3 July 2024 – Today Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage ...
OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ Nantes, France – July 1 st , 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR...
Message Board Posts | OSE Immunotherapeutics SA (OTCMKTS:ORPOF)
Subject | By | Source | When |
---|---|---|---|
ORPOF: inactive security. FINRA deleted symbol: | Renee | investorshub | 12/27/2022 10:13:32 PM |
OSE Immunotherapeutics Announces Dosing of the First Healthy | Bandicoot_Inv | investorshub | 05/26/2021 8:41:46 AM |
https://www.globenewswire.com/news-release/2021/05/26/2236023/0/en/OSE-Immunothe | Bandicoot_Inv | investorshub | 05/26/2021 8:40:58 AM |
News, Short Squeeze, Breakout and More Instantly...
OSE Immunotherapeutics SA Company Name:
ORPOF Stock Symbol:
OTCMKTS Market:
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 Ingelheim, Germany and Nantes, France, 3 July 2024 – Today Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage ...
OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ Nantes, France – July 1 st , 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR...
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies NANTES, France, June 24, 2024 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced that the Company has entered into a commercial ...